Foundation Awards Devices to York County EMS Departments to Assist in
Monitoring for Presence of Carbon Monoxide
ROCK HILL, York County, S.C.--(BUSINESS WIRE)--Nov. 7, 2017--
Masimo (NASDAQ:
MASI) announced today that The Jeffrey Lee Williams Foundation has
distributed 20 Masimo Rad-57® Pulse CO-Oximeters®
to EMS departments in York County, South Carolina, with the majority
going to Piedmont Medical Center EMS. The Foundation purchases equipment
that assists in monitoring for the presence of carbon monoxide (CO) and
donates it to the community and local fire and first response agencies.
The Rad-57s were awarded to the departments at an event on November 6.
This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20171107005658/en/
The Jeffrey Lee Williams Foundation Presents Masimo Rad-57® Pulse CO-Oximeters® to Members of the Piedmont Medical Center EMS (York County, South Carolina) (Photo: Business Wire)
The Jeffrey Lee Williams Foundation was founded in 2013 to honor the
tragic loss of Jeannie Williams’ son Jeffrey at the age of 11 to CO
poisoning. Its mission is to help prevent CO poisoning by facilitating
the distribution and placement of equipment to detect and monitor for
CO. Currently, the Foundation is working in York County to sponsor the
distribution of 2,000 CO alarms among all 18 fire districts in York
County for installation in residential homes, the distribution of 45
“always-on” CO monitors among fire departments and EMS departments, and
the distribution of the 20 Masimo Rad-57s to first responders and EMS
departments.
CO poisoning is a leading cause of unintentional poisoning deaths in the
United States.1 In addition, just one severe CO exposure
event nearly doubles the risk of premature death, and consistent CO
exposure may cause long-term heart and brain damage.2,3 Even
mild levels of CO circulating in the blood rob the heart and brain of
oxygen, which can cause mental confusion, leading to poor decision
making and increasing the risk of heart disease or stroke – two
conditions that account for nearly 50% of on-duty firefighter deaths.4,5
Rad-57 provides oxygen saturation, pulse rate, and perfusion index
measurements using SET® Measure-through Motion and Low
Perfusion™ pulse oximetry. In addition, it includes SpCO®, a
noninvasive rainbow® parameter, to measure the amount of
carboxyhemoglobin in red blood cells; carboxyhemoglobin forms after
exposure to CO. Noninvasive SpCO monitoring may lead to the
identification of elevated CO levels that might otherwise go undetected
in front-line settings.
Amber Williams, Co-founder of The Jeffrey Lee Williams Foundation, South
Carolina, “We are thrilled to offer Piedmont Medical Center EMS and two
other rescue squads the Rad-57s! These devices will provide quick,
noninvasive, objective data to responders to assist in the
identification and treatment of CO exposure in our community.”
Jeannie Williams, Co-founder, added, “Thank you Masimo for your support
as we work to help others in Jeffrey’s memory.”
Joe Kiani, Founder and CEO of Masimo, said, “We are saddened by the loss
of life due to CO poisoning and delighted to help support The Jeffrey
Lee Williams Foundation’s important work. We hope that Rad-57 and SpCO
technology can help to identify elevated CO levels in York County EMS
responders, firefighters, and civilians.”
SpCO is intended to be used to monitor CO levels in the blood and is not
intended to be used as the sole basis for making diagnosis or treatment
decisions related to carbon monoxide poisoning. SpCO monitoring is not
intended to replace laboratory blood testing; blood samples should be
analyzed by laboratory instruments prior to clinical decision making.
@MasimoInnovates |
#Masimo
References
1. Carbon Monoxide Exposures, United States, 2000-2009. Morbidity and
Mortality Weekly Report. Centers for Disease Control and Prevention. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6030a2.htm.
2.
Hampson NB et al. Increased long-term mortality among survivors of acute
carbon monoxide poisoning. Crit Care Med. 2009; 37(6):1941-47.
3.
Bledsoe BE. The heart dangers of CO: Understanding cardiovascular risks
to responders from CO exposure. J Emerg Med Svcs. 2007; 32:54-59.
4.
Jakubowski G. The Invisible Incidents: How to respond to CO alarms. FireRescue
Magazine. 2004; 22(11):52-55.
5. Bledsoe BE. The Perils of CO. FireRescue
Magazine. September 2005.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 17 of the top 20
hospitals listed in the 2017-18 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect™ (MOC-9™) interface, enabling other companies to
augment Root with new features and measurement capabilities. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor, iSpO2®
pulse oximeter for smartphones, and the MightySat™ fingertip pulse
oximeter. Additional information about Masimo and its products may be
found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.
*The use of the trademark Patient SafetyNet
is under license from University HealthSystem Consortium.
References
1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
2.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;338.
3.
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events
and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology.
2010; 112(2):282-287.
4. Taenzer AH et al. Postoperative
Monitoring – The Dartmouth Experience. Anesthesia Patient Safety
Foundation Newsletter. Spring-Summer 2012.
5. McGrath SP et al.
Surveillance Monitoring Management for General Care Units: Strategy,
Design, and Implementation. The Joint Commission Journal on Quality
and Patient Safety. 2016 Jul;42(7):293-302.
6. Estimate: Masimo
data on file.
7. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Rad-57® Pulse CO-Oximeter®
and SpCO®. These forward-looking statements are based on
current expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and many
of which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to our
belief that Masimo's unique noninvasive measurement technologies,
including Masimo Rad-57 Pulse CO-Oximeter and SpCO, contribute to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; as well as other factors
discussed in the "Risk Factors" section of our most recent reports filed
with the Securities and Exchange Commission ("SEC"), which may be
obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171107005658/en/
Source: Masimo
The Jeffrey Lee Williams Foundation
Jeannie and Amber
Williams
info@jeffreysfoundation.org
jeffreysfoundation.org
or
Masimo
Evan
Lamb
949-396-3376
elamb@masimo.com